Loading
A rarer EGFR mutation (~2% of lung cancers) that does not respond to standard EGFR pills and needs its own drugs.
EGFR exon 20 insertions are a rarer class of EGFR mutation in non-small-cell lung cancer, making up a minority of EGFR-mutant disease. Structurally the insertion blocks first- to third-generation EGFR tyrosine kinase inhibitors, so the standard EGFR pills that work for exon 19 deletions and L858R do not work here. Amivantamab with chemotherapy, tested in PAPILLON, is the first-line standard, and sunvozertinib, approved in 2025, is the oral option following the withdrawal of mobocertinib. Readers meet the term on the drug pages for amivantamab, mobocertinib and sunvozertinib and within the receptor tyrosine kinase activation pathway. It matters because it is the clearest example of an EGFR alteration that needs its own drugs rather than the class default.
In plain words · A growth receptor that is mutated in some lung cancers and overproduced in others; the first great success of targeted pills.
Showing the target this term concerns: EGFR.
The glossary entry explains the word; the readout page carries the scoring rule, the thresholds approvals use, the companion diagnostics and the tests.
Shares Amivantamab, Receptor tyrosine kinase activation, EGFR-mutated non-small-cell lung cancer, EGFR.
Shares Sunvozertinib, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Sunvozertinib, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Sunvozertinib, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Sunvozertinib, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Amivantamab, Receptor tyrosine kinase activation, EGFR-mutated non-small-cell lung cancer, EGFR.
Shares Amivantamab, EGFR-mutated non-small-cell lung cancer, EGFR, Non-small-cell lung cancer.
Shares Mobocertinib, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.